Log in
Enquire now
Biocross, S.L.

Biocross, S.L.

Biocross is a Boecillo, Spain-based biotech company developing diagnostic tools for the treatment of neurodegenerative diseases.

OverviewStructured DataIssuesContributors

Contents

biocross.es
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Diagnosis
Diagnosis
Biotechnology
Biotechnology
Biology
Biology
Technology
Technology
Location
Province of Valladolid
Province of Valladolid
B2X
B2B
B2B
CEO
Matthew Mittino
Matthew Mittino
Spun Out From
Spanish National Research Council
Spanish National Research Council
Number of Employees (Ranges)
11 – 50
Full Address
Parque tecnológico de Boecillo Avda. Francisco Valles, 8, Boecillo 47151 Valladolid Spain
Investors
SODICAL
SODICAL
0
CRB Inverb
CRB Inverb
Latest Funding Round Date
April 2018
Latest Funding Type
Series A
Series A

Other attributes

Company Operating Status
Active

Biocross is a biotech company focused on the development of integrated, non-invasive diagnostic solutions for the treatment of neurodegenerative diseases. These cost-effective tools enable detection of dementia at all stages of the illness, including the early asymptomatic phase. The company was founded in 2005 and is headquartered in Boecillo, Spain.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Biocross, S.L.

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.